Furthermore, an over-expression of IGF2BP2 (mRNA binding proteins 2) has been associated with a poor prognosis of the disease in multiple human cancers, as well as, with a shorter survival and poor prognosis in acute myelocytic leukemia, low-grade gliomas, breast , esophageal, hepatocellular, head and neck squamous cell, pancreatic ductal adenocarcinoma and gallbladder carcinomas (Wang et al., 2021). Here, IGF2BP2 is linked to pancreatic ductal adenocarcinoma.